Cargando…

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin

AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover st...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jin Ah, Lee, Soo-Yun, Kim, Tae-Eun, Kim, Jung-Ryul, Kim, Chin, Huh, Wooseong, Ko, Jae-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354432/
https://www.ncbi.nlm.nih.gov/pubmed/25767371
http://dx.doi.org/10.2147/DDDT.S76591
_version_ 1782360763227176960
author Jung, Jin Ah
Lee, Soo-Yun
Kim, Tae-Eun
Kim, Jung-Ryul
Kim, Chin
Huh, Wooseong
Ko, Jae-Wook
author_facet Jung, Jin Ah
Lee, Soo-Yun
Kim, Tae-Eun
Kim, Jung-Ryul
Kim, Chin
Huh, Wooseong
Ko, Jae-Wook
author_sort Jung, Jin Ah
collection PubMed
description AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover study, 24 healthy male subjects were administered lobeglitazone (0.5 mg) for 1–12 days with warfarin (25 mg) on day 5 in one period. After a washout interval, subjects were administered warfarin (25 mg) alone in the other period. Pharmacokinetics of R- and S-warfarin and lobeglitazone, as well as pharmacodynamics of warfarin, as measured by international normalized ratio (INR) and factor VII activity, were assessed. RESULTS: The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for area under the curve from time zero to the time of the last quantifiable concentration (AUC(last)) for warfarin + lobeglitazone: warfarin alone were 1.0076 (90% CI: 0.9771, 1.0391) for R-warfarin and 0.9880 (90% CI: 0.9537, 1.0235) for S-warfarin. The maximum observed plasma concentration (C(max)) values were 1.0167 (90% CI: 0.9507, 1.0872) for R-warfarin and 1.0028 (90% CI: 0.9518, 1.0992) for S-warfarin, both of which were contained in the interval 0.80–1.25. Lobeglitazone had no effect on the area under the effect–time curve from time 0 to 168 hours (AUEC) of INR and factor VII activity, as demonstrated by the GMRs of 1.0091 (90% CI: 0.9872, 1.0314) and 0.9355 (90% CI: 0.9028, 0.9695), respectively. In addition, the pharmacokinetics of lobeglitazone was also unaffected by warfarin. CONCLUSION: Concomitant administration of lobeglitazone and warfarin was well tolerated. Lobeglitazone had no meaningful effect on the pharmacokinetics or pharmacodynamics of warfarin. These findings indicate that lobeglitazone and warfarin can be coadministered without dosage adjustments for either drug.
format Online
Article
Text
id pubmed-4354432
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43544322015-03-12 Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin Jung, Jin Ah Lee, Soo-Yun Kim, Tae-Eun Kim, Jung-Ryul Kim, Chin Huh, Wooseong Ko, Jae-Wook Drug Des Devel Ther Original Research AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover study, 24 healthy male subjects were administered lobeglitazone (0.5 mg) for 1–12 days with warfarin (25 mg) on day 5 in one period. After a washout interval, subjects were administered warfarin (25 mg) alone in the other period. Pharmacokinetics of R- and S-warfarin and lobeglitazone, as well as pharmacodynamics of warfarin, as measured by international normalized ratio (INR) and factor VII activity, were assessed. RESULTS: The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for area under the curve from time zero to the time of the last quantifiable concentration (AUC(last)) for warfarin + lobeglitazone: warfarin alone were 1.0076 (90% CI: 0.9771, 1.0391) for R-warfarin and 0.9880 (90% CI: 0.9537, 1.0235) for S-warfarin. The maximum observed plasma concentration (C(max)) values were 1.0167 (90% CI: 0.9507, 1.0872) for R-warfarin and 1.0028 (90% CI: 0.9518, 1.0992) for S-warfarin, both of which were contained in the interval 0.80–1.25. Lobeglitazone had no effect on the area under the effect–time curve from time 0 to 168 hours (AUEC) of INR and factor VII activity, as demonstrated by the GMRs of 1.0091 (90% CI: 0.9872, 1.0314) and 0.9355 (90% CI: 0.9028, 0.9695), respectively. In addition, the pharmacokinetics of lobeglitazone was also unaffected by warfarin. CONCLUSION: Concomitant administration of lobeglitazone and warfarin was well tolerated. Lobeglitazone had no meaningful effect on the pharmacokinetics or pharmacodynamics of warfarin. These findings indicate that lobeglitazone and warfarin can be coadministered without dosage adjustments for either drug. Dove Medical Press 2015-03-02 /pmc/articles/PMC4354432/ /pubmed/25767371 http://dx.doi.org/10.2147/DDDT.S76591 Text en © 2015 Jung et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Jung, Jin Ah
Lee, Soo-Yun
Kim, Tae-Eun
Kim, Jung-Ryul
Kim, Chin
Huh, Wooseong
Ko, Jae-Wook
Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
title Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
title_full Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
title_fullStr Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
title_full_unstemmed Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
title_short Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
title_sort lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354432/
https://www.ncbi.nlm.nih.gov/pubmed/25767371
http://dx.doi.org/10.2147/DDDT.S76591
work_keys_str_mv AT jungjinah lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin
AT leesooyun lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin
AT kimtaeeun lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin
AT kimjungryul lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin
AT kimchin lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin
AT huhwooseong lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin
AT kojaewook lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin